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4 MeV and 12 MeV (20%, 14% and 6% cases respectively) were 
used. In 54% cases applicator size was 5 cm in diameter. The 
smallest was 4 cm (15%) and the largest 7 cm (used only in 5% 
cases). Treatment applicators with 0°, 15° and 30° beveled 
tips were used (32%, 41% and 26% cases respectively). In 60% 
cases no bolus was needed; 0.5 cm bolus was used in 44 cases 
(29%). In all treatment procedures aluminium-lead shielding 
plates were used, 85% of which were 0.5 cm thick. The mean 
thickness of irradiated breast gland was 2.1 cm between 0.8 
cm and 3 cm. PTV volume (volume of tissue encompassed by 
the 90% isodose line) was rather small, with average volume 
of 42.50 cc ranging from 15.00 cc to 92.10 cc. 
Conclusions: Intraoperative radiotherapy is proved to be 
effective, tolerable and perspective treatment procedure. 
The external beam course afterwards was shortened by 1 
week.  
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Purpose/Objective: Long term follow-up (f/u) of patients 
(pts) undergoing accelerated partial breast irradiation (APBI) 
with single-fraction (SF) intraoperative radiotherapy (IORT) 
following breast conserving (BC) surgery is limited. We report 
our institutional experience with SF IORT in early stage 
breast cancer with respect to local control and toxicity.  
Materials and Methods: Records were reviewed for 64 
consecutive pts who received SF IORT from 2002 to 2014 at 
our institution. Of these, 47 pts were prospectively enrolled 
in an institutional IRB-approved phase I-II study between 2002 
and 2008. Eligible pts were ≥40 years with stage 0, I or II 
breast cancer measuring ≤2.5 cm without nodal involvement 
and were all screened with breast MRI for multifocal (MF) or 
multicentric (MC) disease (both exclusion criteria) (EC). 8 of 
the 47 pts did not fully meet eligibility criteria and declined 
additional surgery or radiation. The remaining 17 patients 
were treated per protocol guidelines between 2009 and 2014. 
IORT was delivered using either a 200 kV orthovoltage source 
or electrons to 15-21 Gy prescribed to the 90% isodose line. 
Results: The median age at treatment was 61 years (range: 
40-84 years). Median f/u time was 88 months (range 1 – 144 
months). Two pts had an ipsilateral breast tumor recurrence 
(IBTR), with one not meeting EC. A third patient with EIC and 
nodal micrometastasis later developed an axillary 
recurrence. All 3 patients had declined further surgery, 
radiation and/or systemic therapy. Overall, 52 of 64 pts (81%) 
received adjuvant systemic therapy consisting of endocrine 
therapy (n=49), chemotherapy (n=5) and/or trastuzumab 
(n=1). For patients who met original protocol guidelines, the 
IBTR rate was 1.6% at 6 years of f/u. On univariate analysis, 
the following factors emerged as significant predictors of 
IBTR: age <50 years (p<0.001), pathologic nodal involvement 
(p<0.001) and lack of any adjuvant systemic therapy 
(p=0.001). There were 2 cases of isolated distant relapses, 
which occurred in patients who had also declined adjuvant 
systemic therapy. Lack of systemic therapy was the only 
significant predictor of distant relapse (p=0.01). All 64 
patients tolerated IORT well with no evidence of grade III or 
higher toxicity. 
Conclusions: APBI using IORT is an inherently desirable 
option for BC therapy in appropriately selected pts. Our 
group has an IBTR rate of 1.6% at 7 years of f/u. We conclude 
that adherence to appropriate clinical guidelines for patient 
selection and strongly advising adherence to 
recommendations for additional surgery, radiation and 
systemic therapy are critical for successful use of APBI using 
SF IORT.  
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Purpose/Objective: In selected patients, partial breast 
irradiation (PBI) could be a good option for delivering 
radiation therapy. Brachytherapy, conformal external 
radiation therapy (EBRT) and intraoperative radiation therapy 
(IORT) are the most common therapies as PBI. Using an 
Intrabeam® device as IORT has been considered expensive 
due to the initial cost of the equipment. 
The purpose of this study is to elucidate the real cost of IORT 
with Intrabeam® in breast cancer, comparing with 
conventional EBRT. 
Materials and Methods: Between Jan-2013 and Nov-2014, 75 
breast cancer patients were treated with IORT during 
conserving surgery in our institution, delivering a dose of 20 
Gy, with treating times adjusted to applicator diameter. 
Costs were estimated with time of surgery theatre 
occupation, radiation oncologist, physicist and technician, 
fungible material, applicators and total equipment cost 
distributed proportionately among patients. For EBRT costs 
calculations, there has been included institutional fares and 
price for distance travelled by patients daily. Also we 
calculated the waiting time that could influence QoL. 
Results: - For the 75 IORT patients, treatment time was 
registered by the device software, with an average of 
24.66min (15.97-49.07min), meaning an added cost of 
327.46€ (212.04-651.6€). Equipment total cost proportion 
was 1600 €/patient. Adding staff time and fungibles, the 
average total cost of the procedure has been 2398.45€ 
(2283.03-2722.6€). For the whole series, the total estimated 
cost has been 201123.75€. 
- The average 75 EBRT cost per patient was 3980.43€, with a 
total cost of 298532.25€ for the 75 patients. Considering daily 
patient routes twice a day, 25 days, total cost will be 
increased to 299376.45€, being a more realistic approach. 
- For the 75 patients treated with Intrabeam®, 98252.70€ 
have been saved, comparing with equivalent EBRT.  
Investigating daily waiting time during EBRT, we have 
compared the difference between the daily treatment 
appointment time and the real treatment time in 12 random 
patients of the previous year. We found an average daily 
delay of 15.9min/patient, that means a total waste of 6h and 
37min/patient for the whole treatment and a total of 497h 
for the 75 patients. As personal cost, the whole group had 
employed more than 20 days waiting to be treated with 
EBRT. 
Conclusions: Despite of the apparent high cost of equipment 
needed, IORT with an Intrabeam® device presents an 
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economical benefit compared to conventional standard EBRT, 
with a saving of 98252.70€ in 75 treated patients. It also 
associates a time profit that may improve QoL. 
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Purpose/Objective: Rationale of accelerated partial breast 
irradiation (APBI) is the prevention of local relapse in breast 
area with the highest probability of recurrences in strictly 
selected patients. Intraoperative Radiotherapy (IORT) is one 
of the most promising techniques of APBI. The aim of this 
study is the preliminary evaluation of toxicity, cosmetic 
effect and 5-years rate of ipsilateral breast recurrences in 
patients treated with exclusive single dose IORT with 
electrons after quadrantectomy (QUAD) for early stage-breast 
cancer. 
Materials and Methods: Between January 2008 and June 
2014 thirty-one women were treated with single dose IORT in 
our Institution. Thirteen were enrolled into a multi-centric 
randomized trial (coordinated by Regina Elena Institute of 
Rome) and eighteen were treated with single dose for age 
and co-morbidities, that contraindicate external beam 
radiotherapy (EBRT). Patients underwent QUAD with sentinel 
lymph node biopsy. All of them were older than 60 years or in 
post-menopausal status, with a single tumour sized 2 cm or 
less, histological proven invasive ductal or lobular carcinoma 
and clinically N0. IORT was delivered with a mobile Linear 
Accelerator (NOVAC7 by SIT) with a total dose of 21 Gy. An 
electron energy 7 to 9 MeV was used. A perspex shield was 
placed under the mammary gland, to reduce dose to the 
chest wall, heart and ipsilateral lung. Acute and late 
toxicities were evaluated one month after the treatment, 
then every three months for two years and every six months 
up to 5 years, according to RTOG scale while cosmetic 
outcomes was assessed by Harvard criteria. 
Results: The median follow-up was 54,6 months (range 5 to 
78). Mean age of the patients was 72,5 years (range: 62-80). 
Pathologic findings identified twenty-six patients as 
infiltrating ductal carcinoma and 5 as infiltrating lobular 
carcinoma. Patients presented N0 or N1mic status, except for 
two cases with N1a, and negative surgical margins. Average 
diameter of applicators was 60 mm (range 40-80). Treatment 
was successfully completed in all patients with an average 
lengthening of the operative time of about 20 minutes. At the 
long follow-up only one woman presented local relapse after 
55 months from IORT; she underwent re-excision followed by 
EBRT. Acute toxicity was G0 in 19 patients, G1 in 8 cases and 
G2 in 4 patients. No G3/G4 toxicities occurred. As early side 
effects 6 patients experienced seromas and one patient 
complained wound healing difficulties. G1/G2 late toxicity 
occurred in 6 patients. No lung or heart toxicities were 
observed. Cosmetic valuation was excellent/good in 25 
patients; 6 cases were scored as fairy/poor. 
Conclusions: IORT with a single dose in early breast cancer is 
feasible and well tolerated technique. In our experience it 
resulted in a significant shortening of radiotherapy time and 
gain in quality of life in elderly patients. In eligible cases 
(according to age and clinical staging) it seems a valid 
treatment option for adjuvant radiotherapy.  
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Purpose/Objective: To evaluate local control and cosmetic 
outcome of intra-operative radiation therapy (IORT) as an 
exclusive treatment of early stage breast cancer in patients 
with criteria as GEC-ESTRO (good candidates). 
Materials and Methods: From October 2008 to December 
2013, 100 patients underwent wide breast cancer excision or 
quadrantectomy followed by IORT on tumor bed with 
accelerated electrons (Novac 7 NRT) at the dose of 21Gy. 
Patients were aging at least 50 years with unicentric, 
unifocal, pT1-2  
Results: The average age was 63.89 (range 50–89) with an 
average follow up of 33 months (range 6–65). The pathologic 
stage of the lesions resulted pT1 in 82 cases (82%), in 
particular: 5 cases pT1a (6,1% on 82 cases), 38 pT1b (46,3%) 
and 39 pT1c (47,6%); 11 cases (11%) was pT2 with a diameter 
of 2,5 cm. 
The Grading was G1 in 21 cases (21%), G2 in 59 cases (59%) 
and G3 in 13 cases (13%). The toxicity, evaluated according 
to the EORTC-RTOG criteria, was G0 (37%) in 37 cases, G1 
(48%) in 48 cases, G2 in 6 case (6%); only 2 was G3 (2%). We 
observed 9 case of lymphocele (9%); there were no infections 
of the surgical wound nor any mastitis, neither in the treated 
quadrant nor in the other ones. 
We observed a light fibrosis in 14 cases (14%), moderate in 9 
(9%) and liponecrosis in 10 cases (10%). As regards local 
control, there was 2 (2%) local relapse and 1 second tumor. 
The global survival was 100%. 
Cosmetic outcome, evaluated in four levels (Danoff and co.), 
was excellent in 17 cases (17%), good in 63 (63%), sufficient 
in 11 cases (11%), never insufficient. 
Conclusions: The IORT in early breast cancer, at the doses 
used in this study on patients according to GEC-ESTRO 
criteria, provided itself as a secure technique, repeatable, 
with good local control and cosmetic outcome.  
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Purpose/Objective: To describe the initial experience of the 
first institution in Portugal in treating early breast cancer 
with intraoperative radiotherapy (IORT) with an electronic 
brachytherapy system. 
Materials and Methods: We retrospectively analyzed the 
data of 30 women who underwent intraoperative irradiation 
during breast conserving surgery between April 2012 and 
November 2014. Treatment was performed in a single 
